BioSpace News Archive

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced results from the ongoing MOMENTUM study (Study 5051-201), a global Phase 2 clinical trial, of SRP-5051, its next-generation treatment for patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping.

Clarus Therapeutics, Inc. today announced that Express Scripts, Inc, one of the leading pharmacy benefit managers (PBMs) in the United States will now cover JATENZO® (testosterone undecanoate) capsules, CIII. JATENZO is the first and only FDA-approved oral testosterone undecanoate for testosterone

Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced that the first patient has been dosed in a new Phase 1/2 clinical trial for AO-176 in relapsed/refractory multiple myeloma.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced that the last participant has completed the 8-week treatment period in DERMIS-1 and DERMIS-2, the Company’s pivotal Phase 3 clinical trials evaluating ARQ-151 (topical roflumilast cream)

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that it will host a virtual research and development day on Wednesday, December 16, 2020 from 12pm – 2pm Eastern Time. This webinar will feature presentations from Key Opinion Leaders (KOLs) Shakeel

Happiness Biotech Group Limited (the “Company” or Nasdaq: HAPP), an innovative China -based nutraceutical and dietary supplements producer, announced today that Happy Buy, the Company’s wholly-owned subsidiary focusing on e-commerce business, has recorded over $3 million sales since this November. Currently Happy Buy carries

On December 7, 2020, GenScript ProBio and Initium Therapeutics announced that Initium Therapeutics has launched a single B-cell based antibody development platform through collaboration with GenScript ProBio.

Menarini Group announced today that it will present the results of two different preclinical studies on MEN1611, a potent and selective phosphatidylinositol 3-kinase inhibitor (PI3Ki) currently in clinical development for the treatment of breast cancer, at the upcoming 2020 San Antonio Breast Cancer Symposium, which will be held virtually on December 8-11.

Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that as part of its ongoing effort to reimagine prescriber education during the COVID-19 pandemic, it has launched a new and innovative peer-to-peer product education program entitled Migraine PeerConnect.

Enliven Therapeutics, a precision oncology company based in Boulder, CO , is announcing its launch from stealth with a bold mission: To help patients with cancer to not only live longer, but live better. Enliven’s approach combines clinically validated biological targets and industry-leading chemistry to design best-in-class and f